Rituximab News and Research

RSS

Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.

Biosimilars reduce financial burden for cancer patients and insurers

Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care.

27 Aug 2026

Low-cost B-cell depleting therapy is as effective as standard treatment for multiple sclerosis

A Norwegian Swedish clinical trial published in the New England Journal of Medicine (NEJM) demonstrates that rituximab, a low-cost B-cell depleting therapy, is as effective as ocrelizumab in newly diagnosed relapsing multiple sclerosis (MS).

2 Jul 2026

Immunotherapy may help women with early ovarian insufficiency to conceive babies

A pilot study from Karolinska Institutet shows that immunotherapy may enable stimulation of egg maturation in women with autoimmune POI (premature ovarian insufficiency) – a condition that usually leads to infertility.

24 Jun 2026

Engineered CAR-T cells offer potential rheumatoid arthritis cure

For the 18 million people living with rheumatoid arthritis, disease management currently means a lifetime of injections-a reality that new research from Tsinghua University may soon begin to change.

22 Jun 2026

EULAR 2026 highlights rising comorbidity risks in rheumatic disease

People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures.

4 Jun 2026

Early glucocorticoid tapering reduces damage in vasculitis maintenance therapy

Glucocorticoids are the cornerstone of initial vasculitis treatment, used to rapidly control inflammation and protect vital organs.

4 Jun 2026

New therapies could help type 1 diabetes care move beyond insulin alone

Disease-modifying therapies for type 1 diabetes are beginning to move care beyond insulin replacement by targeting immune dysregulation, beta-cell stress, and preservation of endogenous beta-cell function. Teplizumab marks a major clinical milestone, but the review emphasizes that durable metabolic remission will likely require earlier screening, better patient selection, and sequential or combination therapies.

18 May 2026

Fifteen-year follow up reveals cure potential in follicular lymphoma

Unlike some other forms of lymphoma, advanced stage follicular lymphoma is considered incurable. But a new analysis of long-term data on patients treated for the disease years ago with standard regimens of immunotherapy and a chemotherapy combination known as CHOP suggests that many of those patients can now be considered cured.

26 Feb 2026

Immunocompromised individuals require multiple Covid booster doses

Vaccinations alone may not be enough to protect people with compromised immune systems from infection, even if the vaccine has generated the production of antibodies, new research from the University of Cambridge has shown.

13 Feb 2026

Scientists engineer AbLecs to overcome cancer's immune evasion tactics

Researchers at MIT and Stanford University have developed a new way to stimulate the immune system to attack tumor cells, using a strategy that could make cancer immunotherapy work for many more patients.

16 Dec 2025

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

10 Dec 2025

Most T-cell/histocyte-rich large B-cell lymphoma patients can safely receive a less toxic treatment

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

8 Dec 2025

New trial shows major survival gains with epcoritamab added to standard R2 therapy

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard second-line regimen versus the standard regimen alone.

7 Dec 2025

Lymphoma resistance mechanisms and future therapies

A new review was published in Volume 12 of Oncoscience on October 13, 2025, titled "Targeted therapies and resistance mechanisms in lymphoma: Current landscape and emerging solutions."

13 Nov 2025

New precision therapies reshape the future of pancreatitis treatment

Pancreatitis remains a major global health burden, encompassing acute pancreatitis (AP), chronic pancreatitis (CP), and autoimmune pancreatitis (AIP).

11 Nov 2025

Rituximab shows remarkable success in adults with relapsing nephrotic syndrome

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome.

5 Nov 2025

How shifting antibodies fuel aging and the new therapies aiming to slow it

This review uncovers how aging reshapes immunoglobulins, particularly IgG, IgM, and IgA, driving inflammation, cellular senescence, and tissue degeneration. By dissecting B-cell dysfunction, glycosylation changes, and Fc receptor pathways, it reveals immunoglobulins as both biomarkers and potential therapeutic targets in aging.

14 Oct 2025

Scientists outline how future therapies could change type 1 diabetes care

Researchers writing in The Lancet review breakthroughs in type 1 diabetes treatment, from immunotherapies that delay onset to stem-cell β-cell replacement and automated insulin delivery. They stress that equitable access, validated surrogate endpoints, and scalable technologies are crucial for lasting impact.

24 Sep 2025

New imaging technique reveals how antibodies reshape cancer cell receptors

A new study shows how the single-molecule organization of receptors in a cellular context determines the function of antibodies, opening up new pathways for the development of cancer immunotherapies.

11 Aug 2025